Our community narratives are driven by numbers and valuation.
Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more
Rating: Buy / Quality recovery compounder Style: Mid-cap consumer compounder with cyclical film-slate exposure Core debate: Is Kinepolis just a movie-theatre operator in a structurally challenged industry, or is it a premium cinema platform with better economics, stronger pricing power, and more durable cash generation than the market gives it credit for? Executive view Kinepolis is not a “cinema recovery trade” in the simple sense.Read more
Pagaya Technologies (NASDAQ: PGY) — Investment Thesis Pagaya Technologies is not a software company. This distinction is the foundation of the entire investment case and is widely misunderstood by the market.Read more
Everpure (NYSE: P) The AI Infrastructure Re-Rating Current price: ~$78 | My fair value estimate: ~$$150 | Timeframe: 12+ months The market is pricing Everpure as an enterprise storage company. That is the wrong category.Read more

Silver X Mining Corp. (TSXV: AGX) Disclaimer This material is provided for informational and educational purposes only and should not be considered financial, investment, legal, tax, or other professional advice.Read more

Valuation In 3–5 years, I think Microsoft becomes even more dominant in enterprise AI, cloud infrastructure, and productivity software. Azure and Copilot are probably the biggest growth drivers, while Windows, Office, LinkedIn, GitHub, and gaming remain huge cash generators.Read more
OceanaGold (OGC) – Investment Memorandum Recommendation: BUY (High Beta Gold Exposure) Target Price: $3.8–4.5/share Upside: +20–30% 1. Investment Thesis OceanaGold represents a deep-value mid-tier gold producer trading at a discount to peers due to its elevated cost profile and mixed jurisdiction exposure.Read more